Evaluating The Effect Of Intravitreal Triamcinolone-Moxifloxacin During Cataract Surgery On Central Macular Edema In Patients With Preexisting Diabetic Retinopathy

Purpose: To evaluate the effect of intravitreal triamcinolone acetonide-moxifloxacin at the time of cataract surgery on central macular edema in patients with preexisting diabetic retinopathy.Setting: Loma Linda University Eye Institute, California, USA.Design: Retrospective observational clinical study.Methods: Retrospective chart review included 75 eyes of 64 patients who had cataract surgery between February 2015 and October 2018 performed by 2 surgeons. Intravitreal injection of triamcinolone-moxifloxacin (15 mg/ 1 mg/mL, 0.2 mL injection with 3.0 mg triamcinolone acetonide and 0.2 mg moxifloxacin) was given at the time of surgery. Visual acuity and central macular thickness (CMT) with optical coherence tomography were recorded at preoperative and postoperative visits.Results: Mean visual acuity (logarithm of the minimum angle of resolution) at 4 to 6 weeks, 6 to 12 weeks, and 12 weeks or more postoperatively was 0.32, 0.35, and 0.43, respectively. Baseline mean CMT of 75 eyes was 294 mu m (SD = 72). Mean CMT 4 to 6 weeks postoperatively for 46 eyes decreased from 299 mu m (78) to 297 mu m(79), with amean decrease of 2 mm(50) (P =.97). MeanCMT 6 to 12 weeks postoperatively for 34 eyes increased from 317 mu m (88) to 344 mu m (111), with a mean increase of 26 mu m (98) (P =.021). Mean CMT 12 weeks or more for 60 eyes increased from 295 mu m (72) to 328 mu m(108), with a mean increase of 33 mu m (85) (P =.0023).Conclusions: Triamcinolone acetonide-moxifloxacin maintained stability of postoperative CMT in patients undergoing cataract surgery with preexisting diabetic retinopathy in the short term, with the greatest effect at 4 to 6 weeks postoperatively. Copyright (C) 2020 Published by Wolters Kluwer on behalf of ASCRS and ESCRS